Share on LinkedInShare on LinkedIn

ARTICLE · 14 JANUARY 2016

Biosimilar Approvals In The US And Canada – Sidestepping The 'Patent Dance'

Resolution of patent issues between drug companies can be the last hurdle to biosimilar market entry in some cases.

CanadaIntellectual Property

A passing moment of social awkwardness between a couple on a dance floor is nothing compared to the situation when the sidestepping is between two companies to avoid a 'patent dance' and there are billions of dollars of biologic drug profits at stake. Resolution of patent issues between drug companies can be the last hurdle to biosimilar market entry in some cases.

The patent dances in the US and Canada are outlined here.

If the biosimilar manufacturer can resolve patent issues quickly, or avoid the 'patent dance' entirely, then it can hit the market sooner. For the original maker of the drug, if the patent dance is avoided before biosimilar drug approval, then it has to chase the biosimilar manufacturer for patent infringement after market approval, while the biosimilar manufacturer is already eating away at market share.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from